Alliance for Pandemic Preparedness

June 10, 2021

Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern

Category:

Topic:

Keywords (Tags): , ,

  • [Pre-print, not peer-reviewed] AX290 and AX677 (AXON Neuroscience), second generation monoclonal antibodies developed specifically to target SARS-CoV-2 variants of concern, were experimentally shown to successfully neutralize the wild-type strain, B.1.1.7 (Alpha), and B.1.351 (Beta) in mouse models.

Kovacech et al. (June 9, 2021). Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern. Pre-print downloaded Jun 10 from https://doi.org/10.1101/2021.06.09.447527